BJMO - volume 9, issue 4, august 2015
T. Feys MBA, MSc
(BELG J MED ONCOL 2015;9:164–7)
Read moreBJMO - volume 9, issue 4, august 2015
P. Specenier MD, PhD
(BELG J MED ONCOL 2015;9:168–72)
Read moreBJMO - volume 8, issue 5, november 2014
Mugdha Deo PhD, F. Cornélis MD, J.F. Baurain MD, PhD
(BELG J MED ONCOL 2014;8(4):136–42)
Read moreBJMO - volume 8, issue 5, november 2014
J. De Grève MD, PhD
(BELG J MED ONCOL 2014;8(4):177–9)
Read moreBJMO - volume 8, issue 5, november 2014
T. Vermassen PhD, S. Rottey MD, PhD
From the 26th till the 30th of September, Madrid was host for the 39th annual congress of the European Society of Medical Oncology (ESMO). The theme of this years’ meeting, that was hosted at the IFEMA – Feria de Madrid, was ‘Precision Medicine in Cancer Care. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.
(BELG J MED ONCOL 2014;8(4):143–6)
Read moreBJMO - volume 8, issue 5, november 2014
J. Kerger MD, PhD
Notwithstanding the fact that no breaking, practice-changing studies were presented in the sessions devoted to gynaecological cancers at this years’ annual ESMO meeting, the strong trend towards targeted therapies was confirmed, in accordance with the general theme of “precision medicine” at this meeting.
(BELG J MED ONCOL 2014;8(4):147–51)
Read moreBJMO - volume 8, issue 5, november 2014
B. Hiddinga MD, J.P. Van Meerbeeck MD, PhD
This report will highlight 10 important studies presented during ESMO 2014, and 4 small but promising future directions in the treatment of NSCLC. The presidential symposium featured two negative studies in a large cohort of non-small cell lung cancer (NSCLC) patients: the MAGRIT and IMPRESS. The other topics include immunotherapy, targeted treatment and biomarkers, development of new drugs in ALK-EML rearranged NSCLC, and prevention of cachexia in NSCLC. Lastly, an important study in malignant pleural mesothelioma (MPM) was presented.
(BELG J MED ONCOL 2014;8(4):152–7)
Read more
Top
